Integra LifeSciences Holdings Corporation (IART)
NASDAQ: IARTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IART stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.03B
- P/E (TTM)
- 77.94
- Forward P/E
- 5.59
- EPS (TTM)
- $0.17
- Dividend yield
- None
- 52-week range
- 8.70 – 20.49
- Day range
- 13.16 – 13.79
- Volume / Avg
- 826.61K / 1.05M
- Beta
- —
- Shares outstanding
- 77.80M
52-week range
IART stock today
On Nov 20, IART ended the session at $13.25, shedding $0.30 (2.21%), versus the S&P 500's 3.70% decline. At this level, IART sits in the middle of its 52-week range of $8.70 to $20.49: 35.3% below the high, set on Jul 28, 2026 and 52.3% above the low. IART is up 6.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.0%.
Integra LifeSciences trades at 77.9x its trailing twelve-month earnings per share of $0.17. Its forward P/E of 5.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Integra LifeSciences
Company profileIntegra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Dr. Stuart M. Essig Ph.D.
- Headquarters
- Princeton, NJ
- Employees
- 4,427
- Website
- integralife.com
Financial highlights
Full financialsIn fiscal 2025, Integra LifeSciences generated $1.64 billion in revenue, up 1.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Integra LifeSciences reported a net loss of $516.5 million, compared with a loss of $6.9 million a year earlier. Gross margin was 50.9% (down from 54.8%) and operating margin -30.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Growth | +1.53% | +4.47% | -1.03% | +0.99% | +12.43% |
| Net income | $-516.47M | $-6.94M | $67.74M | $180.55M | $169.07M |
| EPS (diluted) | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 |
Analyst forecast
ForecastConsensus (12 analysts)
hold
Avg. price target
$15.67+18.26%
- Strong buy 1
- Buy 2
- Hold 7
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 21, 2026
- EPS actual vs est.
- $0.59 vs $0.56
- Surprise
- +5.36%
IART news
All IART news- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IARTPR Newswire
- Integra LifeSciences to Present at the 2026 UBS Global Healthcare ConferenceGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IARTPR Newswire
- Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual MeetingGlobeNewswire
- Integra: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Integra (IART) Q3 2026 Earnings Call TranscriptNasdaq
- Integra LifeSciences Posts Q3 Profit; Reaffirms FY26 OutlookNasdaqIART, SUN
- Integra LifeSciences Swings To Earnings In Q3; Guides Q4, FY26Nasdaq
Integra LifeSciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs IART |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs IART |
| SGPSpyGlass Pharma Inc. | 30.43 | -1.14% | $1.02B | vs IART |
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs IART |
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs IART |
| AORTArtivion Inc. | 18.16 | -2.00% | $886.02M | vs IART |
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs IART |
| KIDSOrthoPediatrics Corp. | 31.74 | -2.37% | $828.75M | vs IART |
Indexes, lists and sector
Integra LifeSciences stock FAQ
What is Integra LifeSciences's stock price today?
IART last traded at $13.25 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.
Does Integra LifeSciences pay a dividend?
No. Integra LifeSciences does not currently pay a regular cash dividend.
What is IART's P/E ratio?
IART trades at a trailing P/E ratio of 77.94 and a forward P/E of 5.59.
Who is Integra LifeSciences's CEO?
Dr. Stuart M. Essig Ph.D. is the chief executive officer of Integra LifeSciences Holdings Corporation, which has about 4,427 employees.
Has IART ever split its stock?
Yes. The most recent IART stock split was a 2-for-1 split on Jan 4, 2017, one of 2 splits on record.
What is the IART 52-week high?
The 52-week high for IART is $20.49 and the 52-week low is $8.70. The stock is currently 35.3% below its high.